Literature DB >> 2916096

Enterococcal bacteremia: analysis of 75 episodes.

R M Gullberg1, S R Homann, J P Phair.   

Abstract

Seventy-five cases of enterococcal bacteremia were analyzed retrospectively. Most patients had serious underlying disease and blood cultures became positive on an average of 27 days after admission. Polymicrobial bacteremia occurred in one-third of the patients. Twenty-two (30%) of the patients died during hospitalization; nine of these deaths were directly due to enterococcal bacteremia. Metastatic infections occurred in seven patients, including five with endocarditis. More than 40% of the patients were receiving antibiotic therapy at the time of bacteremia; cephalosporins were being administered to 56% of these. Thirty-eight patients were treated with two antibiotics. The commonest regimen was ampicillin and gentamicin; 90% of these patients responded. Eighteen patients were treated with only one antibiotic; 89% of these patients responded. Nineteen patients received no antibiotic therapy; the majority of these patients responded despite lack of therapy. Two-drug regimens are not always required for the treatment of enterococcal bacteremia, and treatment must be tailored to the particular clinical situation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2916096     DOI: 10.1093/clinids/11.1.74

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  20 in total

Review 1.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

2.  Evaluation of a commercial microtiter system (MicroScan) using both frozen and freeze-dried panels for detection of high-level aminoglycoside resistance in Enterococcus spp.

Authors:  S A Fuller; D E Low; A E Simor
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

3.  Isolation of three strains of beta-lactamase-producing Enterococcus faecalis in Argentina.

Authors:  H Lopardo; L Casimir; C Hernández; E A Rubeglio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

Review 4.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

5.  Bacteremia caused by hemolytic, high-level gentamicin-resistant Enterococcus faecalis.

Authors:  M M Huycke; C A Spiegel; M S Gilmore
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

Review 6.  Recovery of uncommon bacteria from blood: association with neoplastic disease.

Authors:  J L Beebe; E W Koneman
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

7.  Species identification and antibiotic susceptibility testing of enterococci isolated from hospitalized patients.

Authors:  J W Gray; D Stewart; S J Pedler
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

8.  Detection of enterococcal high-level aminoglycoside resistance with MicroScan freeze-dried panels containing newly modified medium and Vitek Gram-Positive Susceptibility cards.

Authors:  D Weissmann; J Spargo; C Wennersten; M J Ferraro
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

9.  Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group.

Authors:  S Gordon; J M Swenson; B C Hill; N E Pigott; R R Facklam; R C Cooksey; C Thornsberry; W R Jarvis; F C Tenover
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

10.  Clinical features, risk factors and outcomes of bacteremia due to enterococci with high-level gentamicin resistance: comparison with bacteremia due to enterococci without high-level gentamicin resistance.

Authors:  Hee-Chang Jang; Shinwon Lee; Kyoung-Ho Song; Jae Hyun Jeon; Wan Beom Park; Sang-Won Park; Hong Bin Kim; Nam Joong Kim; Eui-Chong Kim; Myoung-Don Oh; Kang Won Choe
Journal:  J Korean Med Sci       Date:  2009-12-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.